Cordis: Cordis reports positive 2-year data for drug-eluting balloon

Cordis today announced positive 24-month results from a study evaluating its Selution SLR drug-eluting balloon (DEB). Selution SLR offers endovascular therapy for de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the popliteal artery (PA). Cordis acquired the DEB technology from MedAlliance for $1.135 billion last fall. The company presented data [...]The post Cordis reports positive 2-year data for drug-eluting balloon appeared first on Drug Delivery Business.